-+ 0.00%
-+ 0.00%
-+ 0.00%
Tandem Diabetes Care Wins FDA Clearance for Tubeless Mobi Insulin Pump
Share
Listen to the news
Tandem Diabetes Care Wins FDA Clearance for Tubeless Mobi Insulin Pump
  • Tandem Diabetes Care received FDA clearance for Tandem Mobi as a tubeless automated insulin delivery system with up to seven-day wear.
  • US commercial launch is planned for the first half of 2027; existing Mobi pumps are compatible with the new tubeless components.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tandem Diabetes Care Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261112487071) on November 13, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending